Xermelo
Payments companies reported to CMS as associated with Xermelo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xermelo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xermelo
These are the largest totals companies reported as associated with Xermelo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Eric Liu | Denver, CO | Surgical Oncology | $87,446.43 |
| Mark Lewis | Murray, UT | Hematology & Oncology | $5,669.25 |
| Boris Naraev | Tampa, FL | Medical Oncology | $4,852.06 |
| Aman Chauhan | San Francisco, CA | Medical Oncology | $4,546.01 |
| Guillaume Pegna | Portland, OR | Medical Oncology | $4,464.72 |
| Daneng Li | Duarte, CA | Medical Oncology | $4,010.25 |
| Michael Morse | Durham, NC | Hematology & Oncology | $3,910.69 |
| Robert Ramirez | Nashville, TN | Medical Oncology | $3,614.93 |
| Jonathan Strosberg | Tampa, FL | Medical Oncology | $3,596.95 |
| Jennifer Eads | Philadelphia, PA | Medical Oncology | $3,541.01 |
Prescribed Xermelo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.